Who
MONTANOVA CAPITAL, LLC
Director
Company insider
Files Form 4 as: Director and 10% owner and Other, Veradermics; Director and 10% owner, Benitec Biopharma.
In numbers
- Trades disclosed
- 56
- Buys
- 6
- Sells
- 1
- Bought
- $41.7M
- Sold
- $80.4M
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 3 Dec 2024
- Last trade
- 20 Aug 2026
- Last filed
- 21 Aug 2026
Companies traded
Activity over time
1 Dec 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 20 Aug 2026filed 21 Aug 2026 | MANE VeradermicsBiotechnology | SEC FORM 4 Code X | —149,000 | filing |
| 20 Aug 2026filed 21 Aug 2026 | MANE VeradermicsBiotechnology | SEC FORM 4 Code X | —151,000 | filing |
| 20 Aug 2026filed 21 Aug 2026 | MANE Veradermicsoption or derivative · Biotechnology | SEC FORM 4 Code X | —149,000 at $0.00 | filing |
| 20 Aug 2026filed 21 Aug 2026 | MANE Veradermicsoption or derivative · Biotechnology | SEC FORM 4 Code X | —151,000 at $0.00 | filing |
| 19 Aug 2026filed 21 Aug 2026 | MANE VeradermicsBiotechnology | SEC FORM 4 Sold | $74.1M690,601 at $107.25 | filing |
| 19 Aug 2026filed 21 Aug 2026 | MANE VeradermicsBiotechnology | SEC FORM 4 Sold | $6.4M59,399 at $107.25 | filing |
| 1 May 2026filed 5 May 2026 | MANE Veradermicsoption or derivative · Biotechnology | SEC FORM 4 Code A | $14.9M149,000 at $100.00 | filing |
| 1 May 2026filed 5 May 2026 | MANE Veradermicsoption or derivative · Biotechnology | SEC FORM 4 Code A | $15.1M151,000 at $100.00 | filing |
| 1 May 2026filed 5 May 2026 | MANE Veradermicsoption or derivative · Biotechnology | SEC FORM 4 Code A | $14.9M149,000 at $100.00 | filing |
| 1 May 2026filed 5 May 2026 | MANE Veradermicsoption or derivative · Biotechnology | SEC FORM 4 Code A | $15.1M151,000 at $100.00 | filing |
| 6 Feb 2026filed 9 Feb 2026 | MANE VeradermicsBiotechnology | SEC FORM 4 Bought | $402K11,183 at $35.97 | filing |
| 6 Feb 2026filed 9 Feb 2026 | MANE VeradermicsBiotechnology | SEC FORM 4 Bought | $707K19,338 at $36.55 | filing |
| 6 Feb 2026filed 9 Feb 2026 | MANE VeradermicsBiotechnology | SEC FORM 4 Bought | $402K11,183 at $35.97 | filing |
| 6 Feb 2026filed 9 Feb 2026 | MANE VeradermicsBiotechnology | SEC FORM 4 Bought | $707K19,338 at $36.55 | filing |
| 5 Feb 2026filed 9 Feb 2026 | MANE VeradermicsBiotechnology | SEC FORM 4 Bought | $138K3,832 at $36.07 | filing |
| 5 Feb 2026filed 9 Feb 2026 | MANE VeradermicsBiotechnology | SEC FORM 4 Bought | $709K19,199 at $36.93 | filing |
| 5 Feb 2026filed 9 Feb 2026 | MANE VeradermicsBiotechnology | SEC FORM 4 Bought | $1.5M38,771 at $37.63 | filing |
| 5 Feb 2026filed 9 Feb 2026 | MANE VeradermicsBiotechnology | SEC FORM 4 Bought | $690K17,835 at $38.67 | filing |
| 5 Feb 2026filed 9 Feb 2026 | MANE VeradermicsBiotechnology | SEC FORM 4 Bought | $659K16,563 at $39.80 | filing |
| 5 Feb 2026filed 9 Feb 2026 | MANE VeradermicsBiotechnology | SEC FORM 4 Bought | $138K3,832 at $36.07 | filing |
News
No headline names them, or the companies they trade most, lately.